Issues: Vax Specific

Anthrax

Hepatitis B

Hib

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2011 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

 

 

Components of
Pneumococcal Vaccine

Excipients Table
Allergens Table
Components Table


Indication

Immunity in infants and children against S. pneumoniae

Active immunization of infants and toddlers against invasive disease caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F).

Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F

Also for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F

Proprietary Name

Pneumovax 23

Prevnar

Prevnar 13

Manufacturer

Merck

Pfizer

Pfizer

Viability

Inactivated

Inactivated

Inactivated

Microorganism

Streptococcus pneumoniae
23-valent serotype
 

Streptococcus pneumoniae 7-valent serotype

Streptococcus pneumoniae 13-valent serotype

Approved Ages

≥  50 years

≥ 2 years in select populations 

6 weeks - 9 years 

6 weeks - 5 years

≥  50 years

Dose

0.5 mL

0.5 mL

0.5 mL

Route

Intramuscular or Subcutaneous

Intramuscular

Intramuscular

Dose form

Solution

Suspension

Suspension

Appearance

Clear, colorless solution

Homogeneous, white suspension

Homogeneous, white suspension

Concentration (per 0.5 mL)

Streptococcus pneumoniae types 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (23 types), 25 mcg each

Streptococcus pneumoniae serotypes 4, 9V, 14, 18C, 19F, and 23F, 2 mcg each

Serotype 6B, 4 mcg

Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides, 2.2 mcg each

6B saccharides, 4.4 mcg

Excipients

None

Diphtheria CRM197, 20 mcg

Aluminum as aluminum phosphate, 0.125 mg

CRM197 carrier protein, 34 mcg

Polysorbate 80, 100 mcg

Succinate buffer, 295 mcg

Aluminum as Aluminum phosphate, 125 mcg

Adjuvants

Aluminum as aluminum phosphate, 0.125 mg

Diphtheria CRM197, 20 mcg

Aluminum phosphate, 0.125 mg

Aluminum as Aluminum phosphate, 125 mcg

Allergens

None

Dry natural rubber

None

Preservatives

Phenol, 0.25%

None

None

Media

Bovine proteins and other macromolecular components

Soy peptone broth

Soy peptone broth

Packaging

Vials, 5-dose, 10 5-dose vials, 10 single-dose vial

Vial, 1 dose (10 per package)

Syringe, (10 per package)

Routine storage

2 to 8° C (35-46° F)

Do not freeze

2 to 8° C (35-46° F)

Do not freeze

2 to 8° C (35-46° F)

Do not freeze

Package Insert date

Oct 2011

July 2009

Jan 2012

updated Janury 2012

This page was last updated on January 24, 2012

© 2012 Institute for Vaccine Safety